Botox: Marketed to treat strabismus and blepharospasm associated with dystonia (disorder of the eye muscles that control blinking)

In a double-blind trial in 126 patients, 62% (40/64) of patients given Botox reported an improvement of at least 1 point on the 4-point Disability Assessment Scale in the principal target of treatment...